In addition to the International and Durie-Salmon staging systems, biological markers, including cytogenetic abnormalities such as presence of translocations including t(4;14), and t(14;16), hypodiploidy, del(17p), and del(13), serum β2-microglobulin levels greater than 2.5 mg/L, an elevated plasma cell labeling index, and detection of circulating plasma cells, are predictors of poor prognosis in newly diagnosed MM patients3,4. The gene discussed is HLA-G; the disease is Miyoshi myopathy.